fig3

From: Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas

Figure 3. Expression of CD22ΔE12 signature genes in Ph⁺/BCR-ABL⁺ BPL. The RMA-normalized gene expression values for leukemia cells obtained from 123 BCR-ABL⁺ patients [GSE13159 (n = 122), GSE13351 (n = 1) were log₂-transformed and mean-centered to the average value for leukemia cells from 225 BCR-ABL^- BPL patients (GSE1187, GSE13159, GSE13351; Ph-like ALL, MLL-R⁺ and t[1;19]/E2A-PBX1⁺ patients excluded)]. To determine the differential expression of each of the leading-edge genes of the CD22ΔE12 transcriptome, linear contrasts were performed for the mean-centered values. Heat map depicts up and down regulated transcripts for mean-centered expression values and clustered according to average distance metric